Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

被引:16
|
作者
Xu, Yanmei [1 ,2 ]
Li, Xia [3 ]
Wang, Hongtao [4 ]
Xie, Pengmu [2 ]
Yan, Xun [2 ]
Bai, Yu [2 ]
Zhang, Tingguo [1 ]
机构
[1] Shandong Univ, Inst Pathol & Pathophysiol, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China
[2] Shandong Shanxian Cent Hosp, Dept Pathol, Heze 274300, Shandong, Peoples R China
[3] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Dept Gynecol & Obster, Natl Clin Res Canc, Tianjin 300060, Peoples R China
关键词
granulosa cell tumors; DNA methylation; histone modifications; tumor suppressor gene; clinicopathological features; HUMAN HEPATOCELLULAR-CARCINOMA; H-CADHERIN CDH13; DNA-METHYLATION; ABERRANT METHYLATION; NONSMALL CELL; BREAST-CANCER; LUNG-CANCER; CLINICAL CHARACTERISTICS; PROGNOSTIC-SIGNIFICANCE; MUTATIONAL ANALYSIS;
D O I
10.3892/mmr.2016.5521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrant epigenetic modification is associated with the development and progression of cancer. Hypermethylation of tumor suppressor gene promoters and cooperative histone modification have been considered to be the primary mechanisms of epigenetic modification. Ovary granulosa cell tumors (GCTs) are relatively rare, accounting for similar to 3% of all ovarian malignancies. The present study assessed hyper-methylation of the cadherin 13 (CDH13), dickkopf WNT signaling pathway inhibitor 3 (DKK3) and forkhead box L2 (FOXL2) promoters in 30 GCT tissues and 30 healthy control tissues using methylation-specific polymerase chain reaction analysis. The data showed that the frequencies of CDH13, DKK3 and FOXL2 promoter methylation were significantly higher in the GCT tissues, compared with the healthy control tissues (86.67, vs. 23.33%; 80, vs. 26.67% and 66.67, vs. 20%, respectively; P<0.001). Immunostaining of enhancer of zeste homolog 2 (EZH2), a histone H3K27 methyltransferase, showed that the EZH2 protein was expressed in 11 of the 30 GCT tissue samples, whereas no EZH2 protein was expressed in the 30 healthy control tissues (P<0.01). These data suggested that hypermethylation of the CDH13, DKK3 and FOXL2 gene promoters, and overexpression of the EZH2 protein were involved in the development of GCT.
引用
收藏
页码:2739 / 2745
页数:7
相关论文
共 50 条
  • [21] Aggressive adult granulosa cell tumor of the ovary without a FOXL2 mutation: A case report
    Watanabe, Koichi
    Abiko, Kaoru
    Minamiguchi, Sachiko
    Maeda, Hirona
    Murakami, Ryusuke
    Kitamura, Sachiko
    Horie, Akihito
    Mandai, Masaki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (07) : 1404 - 1409
  • [22] FOXL2 mutation is prevalent in metastatic adult granulosa cell tumors and is associated with improved survival
    MacArthur, Emily
    Garrett, Alison
    Wu, Sharon
    Xiu, Joanne
    Brown, Jubilee
    Holloway, Robert
    Herzog, Thomas
    Thaker, Premal
    Korn, Michael
    Courtney-Brooks, Madeleine
    Sukumvanich, Paniti
    Buckanovich, Ronald
    Edwards, Robert
    Mahdi, Haider
    Taylor, Sarah
    Berger, Jessica
    Olawaiye, Alexander
    Boisen, Michelle
    Coffman, Lan
    Jones, Nathaniel
    Lesnock, Jamie
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S162 - S163
  • [23] A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary
    Kommoss, Stefan
    Gilks, Cyril Blake
    Penzel, Roland
    Herpel, Esther
    Mackenzie, Robertson
    Huntsman, David
    Schirmacher, Peter
    Anglesio, Michael
    Schmidt, Dietmar
    Kommoss, Friedrich
    HISTOPATHOLOGY, 2014, 64 (03) : 380 - 388
  • [24] FOXL2 Mutation Status in Ovarian Adult Granulosa Cell Tumors with an Extensive Fibrothecomatous Component
    Monroig-Bosque, Paloma
    Walker, Erika
    Coffey, Donna
    Crumley, Suzanne
    Deavers, Michael
    Olsen, Randall
    Masand, Ramya
    Okoye, Ekene
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1110 - 1111
  • [25] FOXL2 Mutation Status in Ovarian Adult Granulosa Cell Tumors with an Extensive Fibrothecomatous Component
    Monroig-Bosque, Paloma
    Walker, Erika
    Coffey, Donna
    Crumley, Suzanne
    Deavers, Michael
    Olsen, Randall
    Masand, Ramya
    Okoye, Ekene
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1110 - 1111
  • [26] Incidental FOXL2 mutated adult granulosa cell tumour of the ovary with thecoma-like foci
    Anne Kristin Fischer
    Birgid Schömig-Markiefka
    Carina Heydt
    Dominik Ratiu
    Peter Mallmann
    Jörn Meinel
    Reinhard Büttner
    Dietmar Schmidt
    Alexander Quaas
    Virchows Archiv, 2023, 483 : 117 - 124
  • [27] Incidental FOXL2 mutated adult granulosa cell tumour of the ovary with thecoma-like foci
    Fischer, Anne Kristin
    Schoemig-Markiefka, Birgid
    Heydt, Carina
    Ratiu, Dominik
    Mallmann, Peter
    Meinel, Jorn
    Buettner, Reinhard
    Schmidt, Dietmar
    Quaas, Alexander
    VIRCHOWS ARCHIV, 2023, 483 (01) : 117 - 124
  • [28] FOXL2 in adult-type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?
    Pilsworth, Jessica A.
    Todeschini, Anne-Laure
    Neilson, Samantha J.
    Cochrane, Dawn R.
    Lai, Daniel
    Anttonen, Mikko
    Heikinheimo, Markku
    Huntsman, David G.
    Veitia, Reiner A.
    JOURNAL OF PATHOLOGY, 2021, 255 (03): : 225 - 231
  • [29] Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary
    Cluzet, Victoria
    Devillers, Marie M.
    Petit, Florence
    Chauvin, Stephanie
    Francois, Charlotte M.
    Giton, Frank
    Genestie, Catherine
    di Clemente, Nathalie
    Cohen-Tannoudji, Joelle
    Guigon, Celine J.
    ONCOGENE, 2020, 39 (09) : 1875 - 1890
  • [30] Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary
    Victoria Cluzet
    Marie M. Devillers
    Florence Petit
    Stéphanie Chauvin
    Charlotte M. François
    Frank Giton
    Catherine Genestie
    Nathalie di Clemente
    Joëlle Cohen-Tannoudji
    Céline J. Guigon
    Oncogene, 2020, 39 : 1875 - 1890